Cyramza’s new cancer indications

The European Commission recently approved two new indications for ramucirumab (Cyramza), which blocks the formation of new blood vessels (angiogenesis) to malignancies.

Firstly, ramucirumab is now indicated in combination with docetaxel for adults with locally advanced or metastatic nonsmall cell lung cancer that progressed after platinumbased chemotherapy.

Secondly, ramucirumab, which blocks vascular endothelial growth factor, is now approved combined with FOLFIRI (irinotecan, folinic acid and 5-fluorouracil) for metastatic colorectal cancer that progresses on or after bevacizumab, oxaliplatin and a fluoropyrimidine.

Latest discussions

  1. Are pharmacists guinea pigs for covid19

    So, still the doctors are working from b...

  2. Are pharmacists guinea pigs for covid19

    VIVA LA PDAU,  VIVA LA CAC After the la...

This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.